Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has arrived after a court recommended denying an injunction on the launch of generics. A US district court in ...
In 2014 Myrbetriq entered the extremely crowded, commoditized market of products with the intent to become leader in the Overactive Bladder (OAB) treatment category. Using TV, social media, apps and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback